Arcadia Biosciences Q4 2024 GAAP EPS $(2.98) Misses $(0.89) Estimate, Sales $1.216M Beat $1.200M Estimate

Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(2.98) per share which missed the analyst consensus estimate of $(0.89) by 234.83 percent. This is a 41.9 percent decrease over losses of $(2.10) per share from the same period last year. The company reported quarterly sales of $1.216 million which beat the analyst consensus estimate of $1.200 million by 1.33 percent. This is a 56.50 percent increase over sales of $777.000 thousand the same period last year.